重新评估利用血色病患者献血的安全性担忧
遗传性血色病(HH)是一种可致铁过载的遗传性铁代谢疾病,临床外显率低但可发生肝硬化、肝细胞癌、糖尿病和心肌病,治疗需定期放血。许多国家(包括美国)的血库不接受HH患者治疗性放血获得的血液,主要担忧为嗜铁菌(如小肠结肠炎耶尔森菌)感染风险及1970年代非自愿献血者丙型肝炎增加的历史。本文综述现有生物学与临床数据,总结允许HH献血者献血中心的临床经验,认为HH患者的血液是安全的,应允许进入献血者库,无令人信服的证据排除该人群作为献血者。
要点
- 遗传性血色病患者治疗性放血获得的血液在许多国家(包括美国)不被血库接受,全球立场不一致。
- 拒绝的主要担忧包括嗜铁菌(如小肠结肠炎耶尔森菌)感染风险及1970年代非自愿献血者丙型肝炎增加的历史。
- 综述现有生物学与临床数据及允许HH献血者献血中心的经验,认为HH患者血液安全,应允许进入献血者库。
核心结论
- 综述认为无令人信服的证据将遗传性血色病患者排除在献血者之外,其血液是安全的,应允许进入献血者库。
研究设计与样本
- 本文为综述,检索并汇总现有生物学与临床数据以及允许HH献血者献血中心的临床经验。
主要发现
- 遗传性血色病临床外显率低,但部分患者可发生肝硬化、肝细胞癌、糖尿病和心肌病。
- 许多国家(包括美国)的血库不接受HH患者治疗性放血获得的血液,全球立场不一致。
- 拒绝理由包括理论上嗜铁菌(如小肠结肠炎耶尔森菌)感染风险增加,以及1970年代非自愿献血者丙型肝炎感染增加的历史担忧。
关键数值与推荐
- 综述汇总现有生物学与临床数据及允许HH献血者献血中心的临床经验,认为HH患者血液安全,应允许进入献血者库。
临床怎么用
- 综述认为无令人信服的证据将遗传性血色病患者排除在献血者之外,其血液应允许进入献血者库。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism that may lead to iron overload. Clinical penetrance is low, however those afflicted may develop cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiomyopathy. Treatment of HH involves regular phlebotomy to reduce the systemic iron burden. In many countries-including the United States-numerous blood centers do not accept donated blood obtained from HH patients during therapeutic phlebotomy and there are inconsistent positions regarding this globally. This refusal of blood is borne out of a few concerns. First, there is a theoretical increase in the infectious risk of these blood products, particularly by siderophilic organisms such as Yersinia enterocolitica. Second, given the increased incidence of hepatitis C infection from nonvoluntary donors in the 1970s, there is a concern that blood units from HH donors may harbor additional risk given the nonvoluntary nature of their presentation. In this review, we examine the existing biological and clinical data concerning infectious risk and summarize clinical experience from centers allowing HH donors, and demonstrate that blood from HH patients is safe and should be allowed into the donor pool. We conclude that there is no convincing evidence to exclude this population from serving as blood donors. (Hepatology 2018;67:1150-1157).
引用
- Winters AC, Tremblay D, Arinsburg S, et al. Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis. Hepatology. 2018. PMID: 28902419. doi:10.1002/hep.29521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。